In an update to their previous 2007 statement, the AHA and ADA recently presented a review of the current literature and key clinical trials regarding blood pressure and glucose control, cholesterol management, aspirin therapy, and lifestyle modification for primary prevention of CVD in patients with type 2 diabetes. Both the AHA and ADA believed an update was in order due to the major changes that have occurred in the past several years in each of the “ABC” elements of diabetes care (HbA1c, blood pressure, and cholesterol), and because CVD remains the leading cause of death among patients with type 2 diabetes.
For a more detailed discussion on the subject, join us at #CMHC 2015 on Thursday October 22 for a CME symposium titled “ A Closer Look at CV Outcomes for Type 2 Diabetes Therapies: Implications for Patient Care,” chaired by Jay S. Skyler, MD and featuring expert faculty Deepak L. Bhatt, MD, MPH, Jennifer B. Green, MD, and Darren K. McGuire, MD, MHSc.
Read the complete update to the Scientific Statement from the AHA and ADA here.
